Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2018 Jan 25



Publication history
Per citare questo articolo


Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698



Panminerva Medica 2018 Jan 25

DOI: 10.23736/S0031-0808.18.03394-3


lingua: Inglese

A clinical update on metformin and lung cancer in diabetic patients

Gaurav GUPTA 1 , Terezinha de JESUS ANDREOLI PINTO 2, Dinesh K. CHELLAPPAN 3, Anurag MISHRA 4, Himaja MALIPEDDI 5, Kamal DUA 6, 7

1 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, India; 2 Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil; 3 School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia; 4 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, India; 5 Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, India; 6 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, Australia; 7 School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India


Diabetes mellitus (DM) is frequently increased in many countries and become a serious health problem worldwide. Diabetes is associated with dysfunction of different organs such as heart, eyes, blood vessels, nerves, and kidneys. There is a strong connection between diabetes and cancer. Metformin is one of the most commonly prescribed oral antidiabetic medicines and it is suggested as the firstline therapy due to its comparatively safe, inexpensive, effective and welltolerated. Some of the in vitro and in vivo investigations proved that metformin may have a direct anticancer action by preventing the proliferation of malignant cells and formations of the colony, inducing arrest of cell cycle and apoptosis and suppressing tumour growth. The antiproliferative mechanism of metformin alone or in combination with various chemotherapeutic agents is complex and involves several beneficial roles. In this regard, clinical studies are required to explain these roles. In the coming future, the use of metformin, alone or in combination with current chemotherapy, might be a conventional approach to effectually manage lung cancer. This minireview provides a critical overview of currently available clinical trials investigating the effects of metformin in lung cancer.

KEY WORDS: Diabetes - Metformin - Lung cancer - AMPK signaling - mTOR pathway

inizio pagina

Publication History

Article first published online: January 25, 2018
Manuscript accepted: January 19, 2018
Manuscript received: November 28, 2017

Per citare questo articolo

Gupta G, Jesus Andreoli Pinto TD, Chellappan DK, Mishra A, Malipeddi H, Dua K. A clinical update on metformin and lung cancer in diabetic patients. Panminerva Med 2018 Jan 25. DOI: 10.23736/S0031-0808.18.03394-3

Corresponding author e-mail